Plain language summary: does race or income status affect the cancer treatments that patients with metastatic castration-sensitive prostate cancer (mCSPC) receive in the United States?

Authors

Birol Emir (ORCID: https://orcid.org/0000-0003-1787-4938)
Hongbo Yang (ORCID: https://orcid.org/0000-0003-2741-8418)
Wei Song (ORCID: https://orcid.org/0000-0002-0677-2429)
Stephen J. Freedland (ORCID: https://orcid.org/0000-0002-8104-6419)
Rickard Sandin
Daniel J. George (ORCID: https://orcid.org/0000-0002-0836-8542)
Rhonda L. Bitting (ORCID: https://orcid.org/0000-0002-5253-0551)
Krishnan Ramaswamy (ORCID: https://orcid.org/0000-0003-0890-0268)
Yilu Lin (ORCID: https://orcid.org/0000-0001-7040-4287)
Zachary William Abraham Klaassen (ORCID: https://orcid.org/0000-0001-7392-8916)
Neeraj Agarwal (ORCID: https://orcid.org/0000-0003-1076-0428)
David Russell
Wei Gao (ORCID: https://orcid.org/0000-0002-4088-3210)
Agnes Hong

Institutions

Tulane University (US)
Cedars-Sinai Medical Center (US)
Duke University (US)
Pfizer (United States) (US)
University of Utah (US)
Augusta University (US)
Huntsman Cancer Institute (US)
Pfizer (Sweden) (SE)
Durham VA Medical Center (US)
Analysis Group (United States) (US)

Publication Details

Journal: Future Oncology
Published: 2025-04-25
DOI: https://doi.org/10.1080/14796694.2025.2485763
Primary Topic: Prostate Cancer Treatment and Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Plain language summary: does race or income status affect the cancer treatments that patients with metastatic castration-sensitive prostate cancer (mCSPC) receive in the United States?

Birol Emir, Hongbo Yang, Wei Song, Stephen J. Freedland et al.

Apr 25, 2025

1 links

Future Oncology

Prostate Cancer Treatment and Research

article

Plain language summary: does race or income status affect the cancer treatments that patients with metastatic castration-sensitive prostate cancer (mCSPC) receive in the United States?

Birol Emir, Hongbo Yang, Wei Song, Stephen J. Freedland, Rickard Sandin, Daniel J. George, Rhonda L. Bitting, Krishnan Ramaswamy, Yilu Lin, Zachary William Abraham Klaassen, Neeraj Agarwal, David Russell, Wei Gao, Agnes Hong

April 25, 2025article en

Abstract

No abstract available for this paper.

Future OncologyVol. 21(11)

Tulane University (US), Cedars-Sinai Medical Center (US), Duke University (US), Pfizer (United States) (US), University of Utah (US), Augusta University (US), Huntsman Cancer Institute (US), Pfizer (Sweden) (SE), Durham VA Medical Center (US), Analysis Group (United States) (US)

No poverty

Openalex Percentile: Top 87%

Prostate Cancer Treatment and Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Plain language summary: does race or income status affect the cancer treatments that patients with metastatic castration-sensitive prostate cancer (mCSPC) receive in the United States? — Birol Emir, Hongbo Yang, et al. · Future Oncology (2025) | TGRS Research Map | TGRS